AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. CTKB
  4. [Form 4] Cytek Biosciences, Inc. Insider Trading Activity

[Form 4] Cytek Biosciences, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Insider transactions by Cytek Biosciences (CTKB): The company's President and CEO and a director, Jiang Wenbin, reported multiple transactions on 08/18/2025 relating to Restricted Stock Units (RSUs) that vested. Several RSU awards converted into shares: 6,758; 11,781; 22,100; and 29,002 RSUs were reported as vested and credited as common stock. To satisfy tax withholding on the vesting, the issuer withheld and surrendered shares in amounts of 1,646; 2,869; 5,382; and 7,062 at an indicated price of $4.06 per share. After these transactions, the filing shows beneficial ownership tallies following each line, with reported direct ownership figures such as 5,321,479 shares following the largest aggregation. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.

Operazioni degli insider di Cytek Biosciences (CTKB): Il presidente e CEO e direttore Jiang Wenbin ha dichiarato pi霉 operazioni in data 18/08/2025 relative a Restricted Stock Units (RSU) divenute esigibili. Diversi premi in RSU sono stati convertiti in azioni: 6.758; 11.781; 22.100; e 29.002 RSU sono stati indicati come maturati e accreditati come azioni ordinarie. Per coprire le ritenute fiscali sulla maturazione, l'emittente ha trattenuto e consegnato azioni nelle quantit脿 di 1.646; 2.869; 5.382; e 7.062 al prezzo indicato di $4,06 per azione. Dopo queste operazioni, il deposito mostra i conteggi della titolarit脿 beneficiaria dopo ogni voce, con cifre di propriet脿 diretta riportate come 5.321.479 azioni dopo la pi霉 grande aggregazione. Il Modulo 4 猫 stato firmato da un procuratore per conto della persona che ha effettuato la segnalazione.

Operaciones de insiders de Cytek Biosciences (CTKB): El presidente, CEO y director Jiang Wenbin inform贸 varias operaciones el 18/08/2025 relacionadas con Restricted Stock Units (RSU) que vestieron. Varios premios en RSU se convirtieron en acciones: 6.758; 11.781; 22.100; y 29.002 RSU se reportaron como ejercidas y acreditadas como acciones ordinarias. Para cubrir la retenci贸n fiscal por la adquisici贸n, el emisor retuvo y entreg贸 acciones por montos de 1.646; 2.869; 5.382; y 7.062 a un precio indicado de $4.06 por acci贸n. Tras estas operaciones, la presentaci贸n muestra los totales de propiedad beneficiaria tras cada l铆nea, con cifras de propiedad directa reportadas como 5.321.479 acciones tras la agregaci贸n mayor. El Formulario 4 fue firmado por un apoderado en nombre de la persona informante.

Cytek Biosciences(CTKB)鞚� 雮措秬鞛� 瓯半灅: 靷灔 瓴� CEO鞚挫瀽 鞚挫偓鞚� Jiang Wenbin鞚� 2025雲� 8鞗� 18鞚检棎 甓岆Μ頇曥爼(vesting)霅� 鞝滍暅欤检嫕(RSU)瓿� 甏�霠悳 鞐煬 瓯半灅毳� 鞁犼碃頄堨姷雼堧嫟. 鞐煬 RSU 靾橃棳攵勳澊 欤检嫕鞙茧 鞝勴櫂霅橃棃鞀惦媹雼�: 6,758欤�; 11,781欤�; 22,100欤�; 氚� 29,002欤缄皜 甓岆Μ頇曥爼霅橃柎 氤错喌欤茧 瓿勳儊霅橃棃鞀惦媹雼�. 甓岆Μ頇曥爼鞐� 霐半ジ 靹戈笀 鞗愳矞歆曥垬毳� 於╇嫻頃橁赴 鞙勴暣 氚滍枆靷姅 臧侁皝 1,646欤�; 2,869欤�; 5,382欤�; 氚� 7,062欤茧ゼ 鞗愳矞歆曥垬頃橃棳 鞝滌稖頄堨溂氅� 響滌嫓霅� 欤茧嫻 臧�瓴╈潃 $4.06鞚挫棃鞀惦媹雼�. 鞚措煬頃� 瓯半灅 頉�, 鞝滌稖靹滌棎電� 臧� 頃氤勲 響滌嫓霅� 靾橃箻鞐� 霐半ジ 鞁れ唽鞙犼秾 頃╆硠臧� 旮办灛霅橃柎 鞛堨溂氅�, 斓滊寑 頃╆硠 頉勳潣 歆侅爲 靻岇湢甓岇潃 5,321,479欤茧 氤搓碃霅橃柎 鞛堨姷雼堧嫟. Form 4電� 鞁犼碃鞚胳潉 雽�鞁犿暣 氩曥爼雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.

Transactions d'initi茅s de Cytek Biosciences (CTKB) : Le pr茅sident-directeur g茅n茅ral et administrateur Jiang Wenbin a d茅clar茅 plusieurs op茅rations le 18/08/2025 relatives 脿 des Restricted Stock Units (RSU) arriv茅es 脿 茅ch茅ance. Plusieurs attributions de RSU ont 茅t茅 converties en actions : 6 758 ; 11 781 ; 22 100 ; et 29 002 RSU ont 茅t茅 d茅clar茅es acquises et cr茅dit茅es en actions ordinaires. Pour couvrir la retenue 脿 la source li茅e 脿 la acquisition, l'茅metteur a retenu et remis des actions pour des montants de 1 646 ; 2 869 ; 5 382 ; et 7 062 au prix indiqu茅 de 4,06 $ par action. Apr猫s ces op茅rations, le d茅p么t montre les totaux de d茅tention b茅n茅ficiaire apr猫s chaque ligne, avec des chiffres de propri茅t茅 directe d茅clar茅s 脿 5 321 479 actions apr猫s la plus grande agr茅gation. Le formulaire 4 a 茅t茅 sign茅 par un mandataire au nom de la personne d茅clarante.

Insider-Transaktionen von Cytek Biosciences (CTKB): Der Pr盲sident, CEO und Direktor Jiang Wenbin meldete mehrere Transaktionen am 18.08.2025 in Zusammenhang mit Restricted Stock Units (RSUs), die f盲llig geworden sind. Mehrere RSU-Zuweisungen wurden in Aktien umgewandelt: 6.758; 11.781; 22.100; und 29.002 RSUs wurden als f盲llig gemeldet und als Stammaktien gutgeschrieben. Zur Begleichung der Steuerabz眉ge bei der F盲lligkeit behielt der Emittent und stellte Aktien in H枚he von 1.646; 2.869; 5.382; und 7.062 zu einem angegebenen Preis von $4,06 pro Aktie zur眉ck. Nach diesen Transaktionen zeigt die Einreichung die Beneficial-Ownership-Summen nach jeder Zeile, mit gemeldeten Direktbesitzzahlen wie 5.321.479 Aktien nach der gr枚脽ten Aggregation. Das Formular 4 wurde von einem Bevollm盲chtigten im Namen der meldenden Person unterzeichnet.

Positive
  • Reporting person holds both President/CEO and Director roles, indicating alignment of management and board interests as disclosed
  • RSU vesting reflects ongoing executive compensation/retention mechanisms with multiple tranches converting to common stock
Negative
  • Shares were withheld and surrendered to satisfy tax obligations (1,646; 2,869; 5,382; 7,062 shares) which reduces net share increases to the reporting person
  • Filing does not show open-market purchases that would increase insider ownership beyond vesting

Insights

TL;DR: Routine executive equity vesting and share-withholding for taxes; no sale or acquisition for cash beyond withholding.

The filing documents scheduled vesting of multiple RSU awards for the President and CEO who is also a director, converting RSUs into common stock on 08/18/2025. The transactions include share withholding to satisfy tax obligations at $4.06 per share for specified lots. This is a standard compensation-related disclosure rather than a market-driven buy/sell signal. Reported post-transaction beneficial ownership levels are provided, indicating continued significant direct ownership by the reporting person.

TL;DR: Material only as insider compensation reporting; no cash sales or new purchases beyond tax-withholding reported.

The data shows conversion of RSUs into shares in several tranches and corresponding surrender of shares to cover withholding. The withholding was executed at $4.06 per share for the disclosed withheld amounts. There are no open-market purchase or sale transactions reported (no proceeds noted), so immediate market-impact implications are limited. This disclosure informs stakeholders about executive equity dilution and insider ownership levels.

Operazioni degli insider di Cytek Biosciences (CTKB): Il presidente e CEO e direttore Jiang Wenbin ha dichiarato pi霉 operazioni in data 18/08/2025 relative a Restricted Stock Units (RSU) divenute esigibili. Diversi premi in RSU sono stati convertiti in azioni: 6.758; 11.781; 22.100; e 29.002 RSU sono stati indicati come maturati e accreditati come azioni ordinarie. Per coprire le ritenute fiscali sulla maturazione, l'emittente ha trattenuto e consegnato azioni nelle quantit脿 di 1.646; 2.869; 5.382; e 7.062 al prezzo indicato di $4,06 per azione. Dopo queste operazioni, il deposito mostra i conteggi della titolarit脿 beneficiaria dopo ogni voce, con cifre di propriet脿 diretta riportate come 5.321.479 azioni dopo la pi霉 grande aggregazione. Il Modulo 4 猫 stato firmato da un procuratore per conto della persona che ha effettuato la segnalazione.

Operaciones de insiders de Cytek Biosciences (CTKB): El presidente, CEO y director Jiang Wenbin inform贸 varias operaciones el 18/08/2025 relacionadas con Restricted Stock Units (RSU) que vestieron. Varios premios en RSU se convirtieron en acciones: 6.758; 11.781; 22.100; y 29.002 RSU se reportaron como ejercidas y acreditadas como acciones ordinarias. Para cubrir la retenci贸n fiscal por la adquisici贸n, el emisor retuvo y entreg贸 acciones por montos de 1.646; 2.869; 5.382; y 7.062 a un precio indicado de $4.06 por acci贸n. Tras estas operaciones, la presentaci贸n muestra los totales de propiedad beneficiaria tras cada l铆nea, con cifras de propiedad directa reportadas como 5.321.479 acciones tras la agregaci贸n mayor. El Formulario 4 fue firmado por un apoderado en nombre de la persona informante.

Cytek Biosciences(CTKB)鞚� 雮措秬鞛� 瓯半灅: 靷灔 瓴� CEO鞚挫瀽 鞚挫偓鞚� Jiang Wenbin鞚� 2025雲� 8鞗� 18鞚检棎 甓岆Μ頇曥爼(vesting)霅� 鞝滍暅欤检嫕(RSU)瓿� 甏�霠悳 鞐煬 瓯半灅毳� 鞁犼碃頄堨姷雼堧嫟. 鞐煬 RSU 靾橃棳攵勳澊 欤检嫕鞙茧 鞝勴櫂霅橃棃鞀惦媹雼�: 6,758欤�; 11,781欤�; 22,100欤�; 氚� 29,002欤缄皜 甓岆Μ頇曥爼霅橃柎 氤错喌欤茧 瓿勳儊霅橃棃鞀惦媹雼�. 甓岆Μ頇曥爼鞐� 霐半ジ 靹戈笀 鞗愳矞歆曥垬毳� 於╇嫻頃橁赴 鞙勴暣 氚滍枆靷姅 臧侁皝 1,646欤�; 2,869欤�; 5,382欤�; 氚� 7,062欤茧ゼ 鞗愳矞歆曥垬頃橃棳 鞝滌稖頄堨溂氅� 響滌嫓霅� 欤茧嫻 臧�瓴╈潃 $4.06鞚挫棃鞀惦媹雼�. 鞚措煬頃� 瓯半灅 頉�, 鞝滌稖靹滌棎電� 臧� 頃氤勲 響滌嫓霅� 靾橃箻鞐� 霐半ジ 鞁れ唽鞙犼秾 頃╆硠臧� 旮办灛霅橃柎 鞛堨溂氅�, 斓滊寑 頃╆硠 頉勳潣 歆侅爲 靻岇湢甓岇潃 5,321,479欤茧 氤搓碃霅橃柎 鞛堨姷雼堧嫟. Form 4電� 鞁犼碃鞚胳潉 雽�鞁犿暣 氩曥爼雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.

Transactions d'initi茅s de Cytek Biosciences (CTKB) : Le pr茅sident-directeur g茅n茅ral et administrateur Jiang Wenbin a d茅clar茅 plusieurs op茅rations le 18/08/2025 relatives 脿 des Restricted Stock Units (RSU) arriv茅es 脿 茅ch茅ance. Plusieurs attributions de RSU ont 茅t茅 converties en actions : 6 758 ; 11 781 ; 22 100 ; et 29 002 RSU ont 茅t茅 d茅clar茅es acquises et cr茅dit茅es en actions ordinaires. Pour couvrir la retenue 脿 la source li茅e 脿 la acquisition, l'茅metteur a retenu et remis des actions pour des montants de 1 646 ; 2 869 ; 5 382 ; et 7 062 au prix indiqu茅 de 4,06 $ par action. Apr猫s ces op茅rations, le d茅p么t montre les totaux de d茅tention b茅n茅ficiaire apr猫s chaque ligne, avec des chiffres de propri茅t茅 directe d茅clar茅s 脿 5 321 479 actions apr猫s la plus grande agr茅gation. Le formulaire 4 a 茅t茅 sign茅 par un mandataire au nom de la personne d茅clarante.

Insider-Transaktionen von Cytek Biosciences (CTKB): Der Pr盲sident, CEO und Direktor Jiang Wenbin meldete mehrere Transaktionen am 18.08.2025 in Zusammenhang mit Restricted Stock Units (RSUs), die f盲llig geworden sind. Mehrere RSU-Zuweisungen wurden in Aktien umgewandelt: 6.758; 11.781; 22.100; und 29.002 RSUs wurden als f盲llig gemeldet und als Stammaktien gutgeschrieben. Zur Begleichung der Steuerabz眉ge bei der F盲lligkeit behielt der Emittent und stellte Aktien in H枚he von 1.646; 2.869; 5.382; und 7.062 zu einem angegebenen Preis von $4,06 pro Aktie zur眉ck. Nach diesen Transaktionen zeigt die Einreichung die Beneficial-Ownership-Summen nach jeder Zeile, mit gemeldeten Direktbesitzzahlen wie 5.321.479 Aktien nach der gr枚脽ten Aggregation. Das Formular 4 wurde von einem Bevollm盲chtigten im Namen der meldenden Person unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jiang Wenbin
(Last) (First) (Middle)
C/O CYTEK BIOSCIENCES, INC.
47215 LAKEVIEW BOULEVARD
(Street)
FREMONT CA 94538
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT AND CEO
3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/18/2025 M 6,758 A (1) 5,268,493 D
Common Stock 08/18/2025 F 1,646(2) D $4.06 5,266,847 D
Common Stock 08/18/2025 M 11,781 A (1) 5,278,628 D
Common Stock 08/18/2025 F 2,869(2) D $4.06 5,275,759 D
Common Stock 08/18/2025 M 22,100 A (1) 5,297,859 D
Common Stock 08/18/2025 F 5,382(2) D $4.06 5,292,477 D
Common Stock 08/18/2025 M 29,002 A (1) 5,321,479 D
Common Stock 08/18/2025 F 7,062(2) D $4.06 5,314,417 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 08/18/2025 M 6,758 (3) (3) Common Stock 6,758 $0 11,272 D
Restricted Stock Units (1) 08/18/2025 M 11,781 (4) (4) Common Stock 11,781 $0 74,618 D
Restricted Stock Units (1) 08/18/2025 M 22,100 (5) (5) Common Stock 22,100 $0 228,373 D
Restricted Stock Units (1) 08/18/2025 M 29,002 (6) (6) Common Stock 29,002 $0 415,701 D
Explanation of Responses:
1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
2. Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
3. The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.
4. The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested.
5. The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.
6. The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested.
/s/ Valerie Barnett, Attorney-in-Fact 08/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What transactions did CTKB insider Jiang Wenbin report on 08/18/2025?

The filing reports multiple RSU vesting events that converted to common stock in amounts of 6,758; 11,781; 22,100; and 29,002 RSUs on 08/18/2025.

Were any shares sold by the insider in this Form 4 for CTKB?

No open-market sales are reported in this Form 4; only shares were withheld and surrendered to satisfy tax withholding on vested RSUs.

How many shares were withheld for taxes and at what price?

The issuer withheld 1,646; 2,869; 5,382; and 7,062 shares to satisfy tax obligations, with the withholding transactions disclosed at $4.06 per share.

What is the reporting person鈥檚 role at Cytek Biosciences (CTKB)?

The reporting person, Jiang Wenbin, is disclosed as President and CEO and as a Director of Cytek Biosciences.

Do the transactions change the insider鈥檚 beneficial ownership substantially?

The Form 4 lists post-transaction beneficial ownership figures after each line (for example 5,321,479 shares after one aggregation), indicating continued significant direct ownership; no material reduction from sales is shown.
Stock CTKB logo
Cytek Biosciences, Inc.

NASDAQ:CTKB

CTKB Rankings

#3264 Ranked by Market Cap
N/A Ranked by Dividends

CTKB Latest News

Sep 10, 2025
Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA
Aug 12, 2025
Cytek Biosciences to Participate in Upcoming Investor Conferences
Aug 6, 2025
Cytek Biosciences Reports Second Quarter 2025 Financial Results
Jul 23, 2025
Cytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025
May 29, 2025
Cytek庐 Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora鈩� Evo Flow Cytometer

CTKB Latest SEC Filings

Aug 20, 2025
[Form 4] Cytek Biosciences, Inc. Insider Trading Activity
Aug 20, 2025
[Form 4] Cytek Biosciences, Inc. Insider Trading Activity
Aug 20, 2025
[Form 4] Cytek Biosciences, Inc. Insider Trading Activity
Aug 20, 2025
[Form 4] Cytek Biosciences, Inc. Insider Trading Activity
Aug 20, 2025
[Form 4] Cytek Biosciences, Inc. Insider Trading Activity

CTKB Stock Data

521.62M
115.42M
9.24%
63.39%
4.01%
Medical Devices
Laboratory Analytical Instruments
United States
FREMONT